Objective:To explore the application value of the new gastric cancer screening scoring system for risk populations in the island of Fujian province.Methods:From April to June 2019, gastric cancer screening was performed on the population of Nanri Island, Putian City, Fujian Province, and epidemiological data of all subjects were prospectively collected. Participants underwent gastroscopy based on gastric cancer risk stratification of the new scoring system. Suspected positive cases further received magnifying endoscopy and biopsy. Additional endoscopic procedures and other surgical treatments were conducted. The detection rates of gastric cancer and precancerous lesions in each group of gastric cancer risk stratification were compared, and the Chi-square test was used for statistical analysis.Results:A total of 1 423 subjects were included, and 19 cases (1.34%) of gastric cancer were detected. The detection rates of gastric cancer were 0.88% (9/1 025) in the low-risk group, 1.76% (6/341) in the medium-risk group, and 7.02% (4/57) in the high-risk group. Paired comparison between the low-risk group and the high-risk group showed significant difference ( χ2=12.364, P=0.003). There was no significant difference between the low-risk group and medium-risk group, or between the medium-risk group and high-risk group ( P>0.05). Among all participants, 87 (6.11%) cases of gastric precancerous lesions were identified. The detection rates of precancerous lesions in the low-risk, medium-risk, and high-risk groups were 6.24% (64/1 025), 5.87% (20/341), and 5.26% (3/57) respectively, with no significant difference among the three groups ( P>0.05) .Conclusion:During gastric cancer screening, the novel gastric cancer screening scoring system helps to stratify gastric cancer risk for population in the islands of Fujian province, serving as a foundation for subsequent detailed endoscopy.

Objective To explore the clinical characteristics and influencing factors of liver injury associated with Qubai Babuqi tablets.Methods Case reports of liver injury associated with Qubai Babuqi tablets in the National Adverse Drug Reaction Monitoring System (ADRMS) from 2012 to 2016 and clinical information of patients with liver injury induced by Qubai Babuqi tablets,who were admitted to the Fifth Medical Center of PLA General Hospital from 2008 to 2017,were collected and retrospectively analyzed.Results A total of 64 patients (59 from case reports in ADRMS and 5 from the Fifth Medical Center of PLA General Hospital) with liver injury induced by Qubai Babuqi tablets were enrolled,including 32 males and 32 females,aged from 10 to 73 years with an average age of (34 ± 13) years.Thirty-three patients (51.6％) were treated with Qubai Babuqi tablets alone,31 patients (48.4％) had combined medication,and 3 of the 64 patients suffered from liver injury again after their remedication of Qubai Babuqi tablets.The median time from medication to liver injury was 33 (2-210) days and the median cumulative dose of Qubai Babuqi tablets was 184.5 (8.0-868.5) g.There were 35 patients (54.7％) with severe liver injury.No significant association was found between the severity of liver injury and the dose of the drug (P ＞ 0.05).But the proportion of patients with severe liver injury treated with combined medication was significantly higher than that of patients with severe liver injury treated with Qubai Babuqi tablets alone [67.7％ (21/31) vs.42.4％ (14/33),x2 =4.282,P =0.042].Among the 64 patients,the liver injury was cured in 31 patients,improved in 21 patients,did not improve in 2 patients,worsened in 2 patients (developed to hepatic encephalopathy and cirrhosis,respectively),and had unknown outcomes in 8 patients.Conclusions About half of the liver injuries caused by Qubai Babuqi tablets were severe ones.The prognosis of liver injury was relatively good and it could be cured or improved in most patients.The combination of other drugs might be the influencing factor of severe liver injury caused by Qubai Babuqi tablets.

Objective To explore the clinical characteristics and influencing factors of liver injury associated with Qubai Babuqi tablets.Methods Case reports of liver injury associated with Qubai Babuqi tablets in the National Adverse Drug Reaction Monitoring System (ADRMS) from 2012 to 2016 and clinical information of patients with liver injury induced by Qubai Babuqi tablets,who were admitted to the Fifth Medical Center of PLA General Hospital from 2008 to 2017,were collected and retrospectively analyzed.Results A total of 64 patients (59 from case reports in ADRMS and 5 from the Fifth Medical Center of PLA General Hospital) with liver injury induced by Qubai Babuqi tablets were enrolled,including 32 males and 32 females,aged from 10 to 73 years with an average age of (34 ± 13) years.Thirty-three patients (51.6％) were treated with Qubai Babuqi tablets alone,31 patients (48.4％) had combined medication,and 3 of the 64 patients suffered from liver injury again after their remedication of Qubai Babuqi tablets.The median time from medication to liver injury was 33 (2-210) days and the median cumulative dose of Qubai Babuqi tablets was 184.5 (8.0-868.5) g.There were 35 patients (54.7％) with severe liver injury.No significant association was found between the severity of liver injury and the dose of the drug (P ＞ 0.05).But the proportion of patients with severe liver injury treated with combined medication was significantly higher than that of patients with severe liver injury treated with Qubai Babuqi tablets alone [67.7％ (21/31) vs.42.4％ (14/33),x2 =4.282,P =0.042].Among the 64 patients,the liver injury was cured in 31 patients,improved in 21 patients,did not improve in 2 patients,worsened in 2 patients (developed to hepatic encephalopathy and cirrhosis,respectively),and had unknown outcomes in 8 patients.Conclusions About half of the liver injuries caused by Qubai Babuqi tablets were severe ones.The prognosis of liver injury was relatively good and it could be cured or improved in most patients.The combination of other drugs might be the influencing factor of severe liver injury caused by Qubai Babuqi tablets.